TD Asset Management Inc. increased its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 2.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 355,698 shares of the biopharmaceutical company’s stock after purchasing an additional 7,198 shares during the quarter. TD Asset Management Inc. owned 0.16% of Alexion Pharmaceuticals worth $46,589,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ALXN. Investors Research Corp purchased a new position in Alexion Pharmaceuticals during the 1st quarter valued at about $27,000. Steward Partners Investment Advisory LLC purchased a new position in Alexion Pharmaceuticals during the 2nd quarter valued at about $28,000. Thor Advisors LLC purchased a new position in Alexion Pharmaceuticals during the 1st quarter valued at about $34,000. NEXT Financial Group Inc purchased a new position in Alexion Pharmaceuticals during the 2nd quarter valued at about $36,000. Finally, Duncker Streett & Co. Inc. purchased a new position in Alexion Pharmaceuticals during the 2nd quarter valued at about $39,000. Institutional investors and hedge funds own 93.77% of the company’s stock.

ALXN has been the subject of several recent research reports. Citigroup dropped their target price on shares of Alexion Pharmaceuticals from $180.00 to $165.00 and set a “buy” rating for the company in a report on Thursday, May 23rd. Wedbush initiated coverage on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 22nd. They set an “outperform” rating and a $173.00 price target on the stock. Goldman Sachs Group reaffirmed a “neutral” rating and set a $142.00 price target on shares of Alexion Pharmaceuticals in a research note on Thursday, May 23rd. TheStreet raised shares of Alexion Pharmaceuticals from a “c” rating to a “b” rating in a research note on Thursday, April 25th. Finally, ValuEngine cut shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 8th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $162.88.

Shares of NASDAQ:ALXN traded up $1.55 during midday trading on Thursday, reaching $109.20. The company had a trading volume of 21,404 shares, compared to its average volume of 2,246,375. The company has a debt-to-equity ratio of 0.26, a current ratio of 4.04 and a quick ratio of 3.56. The company’s fifty day simple moving average is $119.99. The stock has a market cap of $24.37 billion, a PE ratio of 15.41, a P/E/G ratio of 1.03 and a beta of 1.65. Alexion Pharmaceuticals, Inc. has a one year low of $92.56 and a one year high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.13 by $0.51. The business had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.18 billion. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. The business’s revenue was up 15.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.07 earnings per share. As a group, equities analysts anticipate that Alexion Pharmaceuticals, Inc. will post 9 earnings per share for the current year.

In other Alexion Pharmaceuticals news, insider Aradhana Sarin sold 578 shares of Alexion Pharmaceuticals stock in a transaction on Friday, June 21st. The shares were sold at an average price of $132.00, for a total value of $76,296.00. Following the completion of the transaction, the insider now owns 30,201 shares of the company’s stock, valued at $3,986,532. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Indrani Lall Franchini sold 4,500 shares of Alexion Pharmaceuticals stock in a transaction on Monday, July 1st. The stock was sold at an average price of $132.78, for a total transaction of $597,510.00. Following the completion of the transaction, the executive vice president now directly owns 29,627 shares of the company’s stock, valued at approximately $3,933,873.06. The disclosure for this sale can be found here. In the last ninety days, insiders sold 428,567 shares of company stock valued at $53,420,869. 4.08% of the stock is currently owned by corporate insiders.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

See Also: What is a Stop Order?

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.